LC
TBPH icon

Lindbrook Capital’s Theravance Biopharma TBPH Stock Holding History

Lindbrook Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14
Closed -$132 – 2927
2024
Q4 		$132 Buy
+14
New +$127 ﹤0.01% 2732
2024
Q3 		– Sell
-53
Closed -$449 – 2908
2024
Q2 		$449 Buy
+53
New +$478 ﹤0.01% 2647
2024
Q1 		– Sell
-280
Closed -$3.15K – 2755
2023
Q4 		$3.15K Buy
+280
New +$2.82K ﹤0.01% 2095
2023
Q1 		– Sell
-132
Closed -$1.48K – 2910
2022
Q4 		$1.48K Buy
132
+99
+300% +$1.04K ﹤0.01% 2359
2022
Q3 		$0 Buy
33
+7
+27% +$66 ﹤0.01% 2900
2022
Q2 		$0 Sell
26
-567
-96% -$5.22K ﹤0.01% 2762
2022
Q1 		$6K Buy
+593
New +$5.81K ﹤0.01% 1547
2020
Q3 		– Sell
-43
Closed -$1K – 1837
2020
Q2 		$1K Hold
43
– – ﹤0.01% 1633
2020
Q1 		$1K Buy
+43
New +$1.08K ﹤0.01% 1561

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Lindbrook Capital's TBPH Position: Q1 2025 in Review

Lindbrook Capital sold out of Theravance Biopharma (TBPH) in Q1 2025, closing a stake of 14 shares — an estimated $132 sold.

Lindbrook Capital first reported a position in TBPH in Q1 2020 and held it in 9 quarters. The position peaked at $6K in Q1 2022. 131 funds tracked by Wall St. Rank hold TBPH as of Q1 2025.

  • Lindbrook Capital reported no remaining Theravance Biopharma position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 14 Theravance Biopharma shares in Q1 2025, an estimated $132.
  • Lindbrook Capital first reported a position in Theravance Biopharma in Q1 2020 and held it in 9 quarters.
  • Lindbrook Capital's Theravance Biopharma position peaked at $6K in Q1 2022.
  • 131 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.